Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy of Sevikar Compared to the Combination of Perindopril/Amlodipine on Central Arterial Blood Pressure in Patients With Moderate to Severe Hypertension.

Trial Profile

Efficacy of Sevikar Compared to the Combination of Perindopril/Amlodipine on Central Arterial Blood Pressure in Patients With Moderate to Severe Hypertension.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Olmesartan medoxomil/amlodipine (Primary) ; Amlodipine; Hydrochlorothiazide; Perindopril
  • Indications Essential hypertension; Hypertension
  • Focus Therapeutic Use
  • Acronyms SEVITENSION
  • Sponsors Daiichi Sankyo Europe
  • Most Recent Events

    • 23 Sep 2015 Results of a post hoc subgroup (diabetic patients) analysis published in the Journal of Clinical Hypertension (Greenwich).
    • 25 Jun 2013 Primary endpoint 'Central-systolic-blood-pressure' has been met.
    • 25 Jun 2013 First findings from this study were revealed at an ESH 2013 poster session, according to a Daiichi Sankyo media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top